Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00772109 · ClinicalTrials.gov registry record · Phase 3
Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults
A Phase 3 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,292
- Enrollment target
NCT00772109 is a Phase 3 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 4,292 participants.
The verdict
NCT00772109, a Phase 3 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,292 participants
- Enrollment target
Study Summary
This study is designed to test lot consistency of three different manufacturing lots and to generate safety and immunogenicity data of the investigational vaccine administered via the ID route. Primary Objective: * To demonstrate lot consistency of the Fluzone ID manufacturing process. * To provide information concerning the immune response of Fluzone ID. Secondary Objectives: Safety * To describe the safety profile of subjects who receive of Fluzone ID.
Interventions
- BIOLOGICAL Influenza Virus Vaccine USP Trivalent Types A and B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,292 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00772109
The ClinicalTrials.gov registry entry for NCT00772109 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Influenza Virus Vaccine USP Trivalent Types A and B is the first listed.
NCT00772109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00772109 about?
NCT00772109 is a clinical study titled "Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults". This study is designed to test lot consistency of three different manufacturing lots and to generate safety and immunogenicity data of the investigational vaccine administered via the ID route. Primary Objective: * To demonstrate lot consistency of the Fluzone ID manufacturing process. * To provid...
What is the current status of trial NCT00772109?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,292 participants. The study started on 2008-10. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00772109?
The interventions under investigation include: Influenza Virus Vaccine USP Trivalent Types A and B (BIOLOGICAL).
Who is sponsoring clinical trial NCT00772109?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.